Cargando…
Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752286/ https://www.ncbi.nlm.nih.gov/pubmed/29988078 http://dx.doi.org/10.1038/s41436-018-0099-0 |
| _version_ | 1783452756432912384 |
|---|---|
| author | Issa, Amalia M. Thorogood, Adrian Joly, Yann Knoppers, Bartha M. |
| author_facet | Issa, Amalia M. Thorogood, Adrian Joly, Yann Knoppers, Bartha M. |
| author_sort | Issa, Amalia M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6752286 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Nature Publishing Group US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67522862019-09-23 Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations Issa, Amalia M. Thorogood, Adrian Joly, Yann Knoppers, Bartha M. Genet Med Comment Nature Publishing Group US 2018-07-10 2019 /pmc/articles/PMC6752286/ /pubmed/29988078 http://dx.doi.org/10.1038/s41436-018-0099-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Comment Issa, Amalia M. Thorogood, Adrian Joly, Yann Knoppers, Bartha M. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| title | Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| title_full | Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| title_fullStr | Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| title_full_unstemmed | Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| title_short | Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| title_sort | accelerating evidence gathering and approval of precision medicine therapies: the fda takes aim at rare mutations |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752286/ https://www.ncbi.nlm.nih.gov/pubmed/29988078 http://dx.doi.org/10.1038/s41436-018-0099-0 |
| work_keys_str_mv | AT issaamaliam acceleratingevidencegatheringandapprovalofprecisionmedicinetherapiesthefdatakesaimatraremutations AT thorogoodadrian acceleratingevidencegatheringandapprovalofprecisionmedicinetherapiesthefdatakesaimatraremutations AT jolyyann acceleratingevidencegatheringandapprovalofprecisionmedicinetherapiesthefdatakesaimatraremutations AT knoppersbartham acceleratingevidencegatheringandapprovalofprecisionmedicinetherapiesthefdatakesaimatraremutations |